



Date: 30/10/2026

To,
The General Manager
BSE Limited
P.J. Towers, Dalal Street,
Mumbai -400 001

Scrip ID: FRESITA
Scrip Code: 519242

Subject: Outcome of Board Meeting held on 30th October, 2026 pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 read with other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Fresita Proteins Limited, at its meeting held today, i.e., Friday, 30th October, 2026, at the Corporate Office of the Company situated at P-212 B, Gate No. 2, Lodhika GIDC, Rajkot – 360021, has considered and approved the following matters:

1. Approval of Unaudited Financial Results

The Board of Directors considered and approved the Unaudited Standalone Financial Results of the Company for the quarter and half year ended 30th September, 2026, along with the Limited Review Report issued by the Statutory Auditors of the Company thereon.

A copy of the aforesaid Unaudited Standalone Financial Results together with the Limited Review Report is enclosed herewith.

2. Shifting of Registered Office of the Company

The Board of Directors considered and approved the proposal for shifting of the Registered Office of the Company from the State of Rajasthan (Alwar) to the State of Gujarat (Rajkot), subject to the approval of the shareholders of

The meeting of the Board of Directors commenced at 05.00 P.M. and concluded at 05.35 P.M.

Kindly take the above information on your records and acknowledge the receipt.

Thanking you,

Yours faithfully,

For, Fresita Proteins Limited

SAVALIYA SHIRISH
DHIRAJBHAI

Digitally signed by SAVALIYA SHIRISH DHIRAJBHAI
DN: c=IN, postalCode=361160, st=GUJARAT, street=JAMNAGAR,319206,
1=JAMNAGAR, o=Personal,
serialNumber=66c831296d0c8b143d466f774473eb103526c4b319206,
2a727b6305d43ca, pseudonymoid=0446725299414ae0f1f0a8b680d537,
2.5.4.20=4980a5787Bbc67661a652aaabf95c16dc6dafef607f8cb8c8eb70,
027166cf, email=C.HIRAG.SAVALIYA31@gmail.COM, cn=SAVALIYA
SHIRISH DHIRAJBHAI

Shirish Dhirajlal Savaliya

Managing Director

DIN: 08721554

FRESITA PROTEINS LIMITED

CIN: L10790RJ1991PLC006353

Reg Off: 2nd Floor, 2, Sai Collection Building, Bus Stand Road, Police Control Room, Alwar Bus Stand Area, Alwar Bus Stand, Alwar, Rajasthan, India, 301001

E-Mail: sardaproteins@yahoo.com, website: www.sardaproteins.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September, 2026

Rs.in Lakhs

Particulars		Quarter Ended on			Half Year ended on	Half Year ended on	Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from operations	81.03	1,299.30	430.38	1,380.33	1,525.84	1,615.84
II.	Other Income	-	548.10	10.54	548.10	10.62	34.98
III.	Total Revenue (I+II)	81.03	1,847.40	440.92	1,928.43	1,536.46	1,650.82
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	29.73	970.32	387.12	1,000.06	1,515.66	1,547.83
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
	Employee Benefit Expenses	12.75	12.15	0.75	24.90	1.50	3.00
	Finance Cost	-	-	-	-	-	-
	Depreciation and Amoritsation Expenses	-	-	-	-	-	0.39
	Other expenses	19.60	643.63	12.59	663.23	28.18	36.09
	Total Expenses (IV)	62.08	1,626.10	400.45	1,688.19	1,545.34	1,587.32
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	18.95	221.30	40.46	240.24	(8.88)	63.51
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	18.95	221.30	40.46	240.24	(8.88)	63.51
VIII.	Extraordinary Items	-	-	-	-	-	-
IX.	Profit/(Loss) before Tax (V-VI)	18.95	221.30	40.46	240.24	(8.88)	63.51
X.	Tax Expense:						
	(1) Current Tax	5.00	55.33	-	60.33	-	18.07
	(2) Deferred Tax	-	-	-	-	-	-
XI.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	13.95	165.97	40.46	179.91	(8.88)	45.44
XII.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XIII.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XIV.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XV.	Profit/(Loss) for the period (IX+XII)	13.95	165.97	40.46	179.91	(8.88)	45.44
XVI.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XVII.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)	13.95	165.97	40.46	179.91	(8.88)	45.44
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	89.76	89.76	17.26	89.76	17.26	89.76
XVIII	Earnings per Equity Share						
	(1) Basic	0.16	1.85	2.34	2.00	(0.51)	0.51
	(2) Diluted	0.16	1.85	2.34	2.00	(0.51)	0.85

**SAVALIYA SHIRISH
DHIRAJBHAI**

Digitally signed by SAVALIYA SHIRISH DHIRAJBHAI
DN: cn=SAVALIYA SHIRISH DHIRAJBHAI, email=SAVALIYA.SHIRISH@SARVAGAN.COM, c=IN, o=SARVAGAN, ou=Personal
Reason: I, the signatory, have approved the document.
Date: 2020.10.12 12:48:05 +05'30'

SHIRISH DHIRAJLAL SAVALIYA
Managing Director
DIN: 08721554

Date :- 30.10.2026
Place :- Rajasthan

FRESITA PROTEINS LIMITED			
CIN: L10790RJ1991PLC006353			
Reg Off: 2nd Floor, 2, Sai Collection Building, Bus Stand Road, Police Control Room, Alwar Bus Stand Area, Alwar Bus Stand, Alwar, Rajasthan, India, 301001			
Email: sardaproteins@yahoo.com, website: www.sardaproteins.com			
BALANCE SHEET AS ON 30th September, 2026			
(Amount in Lakhs)			
Sr. No.	Particulars	As at 30.09.2026 (In Rs.)	As at 31.03.2026 (In Rs.)
		(Un-Audited)	(Audited)
I.	ASSETS		
1	Non-current assets	-	-
	(a) Property, Plant & Equipments & Intangible Assets	1.33	0.60
	(b) Financial Assets :		
	(i) Investment	-	-
	(ii) Deferred Tax Asset	12.04	12.04
	(iii) Loan & Advances	216.87	216.36
	(iv) Others	-	-
	Total Non-Current Asset	230.24	229.00
2	Current assets	-	-
	(a) Inventory	-	-
	(b) Financial Asset	-	-
	(i) Investment	-	-
	(ii) Trade Receivable	2,477.21	414.16
	(iii) Cash and Cash equivalent	1.90	751.93
	(iv) Bank Balance other than (iii) above	-	-
	(v) Short Term Loan	7,258.96	7,258.23
	(vi) Others (Advances)	-	-
	(c) Current Tax Assets (Net)	-	-
	(d) Other Current Asset	15.87	12.20
	Total Current Asset	9,753.95	8,436.52
	TOTAL ASSET	9,984.18	8,665.52
II.	EQUITY AND LIABILITIES		
A	Equity		
	(a) Share Capital	975.45	975.45
	(b) Reserves and Surplus	7,825.22	7,645.29
	Total Equity	8,800.67	8,620.74
B	Liabilities		
1	Non-Current Liabilities		
	(a) Financial Liabilities	-	-
	(i) Borrowings	-	-
	(c) Deferred tax liabilities / Asset	-	-
	(d) Othe Non-Current Liabilities	-	-
	Total Non-Current Liabilities	-	-
2	Current Liabilities		
	(a) Financial liabilities		
	(i) Borrowings	15.50	15.50
	(ii) Trade payables	1,058.75	3.11
	(A) total outstanding dues of micro enterprises and small enterprises	-	-
	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises	1,058.75	3.11
	(b) Other Current Liabilities	-	-
	(i) Duties & Taxes	28.98	9.70
	(c) Provisions	80.29	16.46
	(d) Current Tax Liabilities (Net)	-	0.01
	Total Current Liabilities	1,183.51	44.78
	TOTAL EQUITY AND LIABILITIES	9,984.18	8,665.52

Notes :-

- The above results were approved by Audit Committee and by Board of Directors in their meeting held on 30th October 2026
- The above stated results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standards and notified under Compaines (Indian Accounting Standards) Rules, 2015 (as amended), specified under Section 133 of Companies Act, 2013 and other accounting principles generally accepted in India
- Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Module Products".
- No Investor Complaints were received during the quarter ended 30-Sep-2026 nor any pending as on 30.09.2026
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period and to make them comparable.

**On behalf of the Board
For, Fresita Proteins Limited**

SAVALIYA SHIRISH
DHIRAJBHAI

Chirag Thummar

Director Name

Managing Director

DIN - 10640822

Date :- 30.10.2026

Place :- Rajasthan

FRESITA PROTEINS LIMITED		
CIN: L10790RJ1991PLC006353		
Reg Off: 2nd Floor, 2, Sai Collection Building, Bus Stand Road, Police Control Room, Alwar Bus Stand Area, Alwar Bus Stand, Alwar, Rajasthan, India, 301001		
EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com		
STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 30th September, 2026		
	(Rs. In Lakhs)	
Particulars	Half Year Ended on 30.09.2026	For Year Ended on 31.03.2026
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	179.91	45.44
Adjustments for:		
Depreciation and amortisation expenses	-	0.39
Finance costs	-	-
Gratuity provision	-	0.00
Kasar vataav	-	-
Rent income	-	-
Dividend income	-	-
Interest income	-	(34.90)
Interest on income-tax refund	-	-
Excess income-tax provision written back	-	-
Excess provision for gratuity written back	-	-
Surplus / loss on sale of property, plant and equipment	-	-
Operating profit before working capital changes	179.91	10.93
Adjustments for:		
Increase / (decrease) in trade and other receivables	(2,067.84)	(7,651.41)
Increase / (decrease) in inventories	-	-
Increase/(decrease) in trade payables, other liabilities and provis	1,138.74	4.62
Cash generated from operations	(749.18)	(7,635.86)
Taxes paid		-
Cash flow before extraordinary items	(749.18)	(7,635.86)
Extraordinary items	-	-
Net cash flow from / (used in) operating activities	(749.18)	(7,635.86)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale of property, plant and equipment	-	-
Purchase of property, plant and equipment	(0.73)	0.99
Purchase of investments	-	-
Interest income	-	34.90
Dividend income	-	-
Net cash used in investing activities	(0.73)	35.89
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of share capital	-	8,335.52
Dividend paid (including dividend distribution tax)	-	-
Proceeds/repayment of pending share application money	-	-
Proceeds from long-term borrowings	-	13.00
Proceeds from short-term borrowings (net)	-	-
Interest & other borrowing costs	(0.11)	-
Interest received from others	-	-
Net cash used in financing activities	(0.11)	8,348.52
NET INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	(750.02)	748.54
Cash and cash equivalents as at beginning (Opening balance)	751.92	3.38
Cash and cash equivalents as at end of the year (Closing balance)	1.90	751.92
Net increase/ decrease	(750.02)	748.54
<div> <div>On behalf of the Board</div> <div> <div>For, Freista Proteins Ltd</div> <div>SAVALIYA SHIRISH</div> <div>DHIRAJBHAI</div> <div>SHIRISH DHIRAJLAL SAVALIYA</div> <div>Managing Director</div> <div>DIN: 08721554</div> </div> </div>		
<div> <div>Date :- 30.10.2026</div> <div>Place :- Rajasthan</div> </div>		

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of Sarda Proteins Limited for the Quarter ended on September 30, 2026 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To
The Board of Directors of
Fresita Proteins Limited**

1. Introduction

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Fresita Proteins Limited ("the Company") for the quarter ended 30 September 2026 ("the Statement"), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. Management's Responsibility

The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with Indian Accounting Standard (Ind AS) 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. Auditor's Responsibility

We conducted our review in accordance with SRE 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the ICAI. A review consists primarily of making inquiries of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Conclusion

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

For, A H Mandaliya & Associates
CHARTERED ACCOUNTANTS
FRN: 146705W

HIREN J
MANDALIYA
Digitally signed by HIREN J
MANDALIYA
Date: 2026.10.30 16:11:25
+05'30'

(Hiren J. Mandaliya)

Partner

Mem. No. :- 140193

UDIN :- 26140193JKXSTV3354

Date :- 30.10.2026

Place :- Ahmedabad